Indivior (INDV) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Indivior published the results on October 29, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Indivior reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• These are Indivior's last results under the INDV ticker. On November 2, 2026 Indivior completed its merger with Supernus Pharmaceuticals and renamed itself Supernus, Inc., which trades under SUPN from November 3, 2026. Supernus is the accounting acquirer, so the deal is accounted for as a reverse acquisition.
• Indivior reports in whole millions, so rows may not foot: U.S. and Rest of World sum to $355 million against net revenue of $356 million. Total SUBLOCADE net revenue, including outside the U.S., was $267 million.
• Indivior redomiciled from the U.K. to the United States on January 26, 2026.

Source: Indivior Q3 2026 results, October 29, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Indivior splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Indivior's Total U.S. revenue was $307 million in Q3 2026, up 15% from $267 million in Q3 2025, 86% of total revenue.
• Indivior's Rest of World revenue was $48.0 million in Q3 2026, up 2% from $47.0 million in Q3 2025, 13% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

Indivior's stand-alone 2026 guidance, unchanged with Q3 results: net revenue of $1,295 million to $1,365 million, total SUBLOCADE net revenue of $1,010 million to $1,050 million, non-GAAP operating expenses of $430 million to $450 million and adjusted EBITDA of $700 million to $740 million. The merger with Supernus closed on November 2, 2026, so this outlook no longer applies.

In its Q3 2026 release, Indivior said:

“Prior to the closing of the merger, Indivior is on track to achieve its previously communicated full year 2026 guidance as a standalone organization.”

“Assuming the merger is completed November 2, 2026, we will operate as a combined company and the guidance will no longer apply.”

Source: Indivior Q3 2026 release, Oct 29, 2026.

This is the company's own guidance as of Oct 29, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the INDV forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net revenue and diluted EPS, in whole millions, each as first reported in that quarter's release.

We do not hold a confirmed date for Indivior's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 29, 2026

Indivior had net revenue of $356 million in Q3 2026, up 13% from $314 million. SUBLOCADE, its monthly buprenorphine injection for opioid use disorder, is most of it: total SUBLOCADE net revenue was a record $267 million, up 22% from $219 million. (Indivior Q3 2026 release, Oct 29, 2026; Indivior Form 10-K, 2025, Feb 26, 2026)

U.S. revenue was $307 million of the $356 million. U.S. SUBLOCADE grew 24% to $252 million, which Indivior said was primarily driven by 17% dispense unit volume growth, with additional benefit from more favorable price/mix and gross-to-net adjustments. Over 583,000 patients in the U.S. had been prescribed SUBLOCADE since launch as of September 30, 2026. (Indivior Q3 2026 release, Oct 29, 2026)

Indivior's other U.S. products are small or winding down. Sublingual and other revenue was $53 million against $51 million. PERSERIS fell to $2 million from $6 million after marketing and promotion stopped in 2024, and OPVEE had no revenue after Indivior discontinued its sales and marketing support during Q3 2025. Rest of World revenue was $48 million against $47 million. (Indivior Q3 2026 release, Oct 29, 2026; Indivior Form 10-K, 2025, Feb 26, 2026)

Indivior sells mostly through U.S. wholesalers. Its 10-K says its three largest customers, all U.S. wholesale pharmaceutical companies, accounted for 51% of global net revenues in 2025, and the largest for 20%. (Indivior Form 10-K, 2025, Feb 26, 2026)

Indivior earned $1.12 per diluted share under GAAP in Q3 2026, on record net income of $137 million, against $0.33 and $42 million a year earlier. Non-GAAP diluted EPS was $1.32 against $0.72. The non-GAAP figure adds back $22 million of operating expense adjustments (mainly corporate initiative transition costs and stock-based compensation) and $8 million of cost of sales adjustments, less $6 million of tax. (Indivior Q3 2026 release, Oct 29, 2026)

Costs fell sharply. GAAP operating expenses were $125 million, down 33% from $187 million, with selling, general and administrative expense at $119 million against $154 million and research and development at $5 million against $33 million. Gross profit rose to $305 million from $230 million, and adjusted EBITDA rose 76% to $211 million, a 59% margin. (Indivior Q3 2026 release, Oct 29, 2026)

Indivior's effective tax rate was 25% in the quarter, against a $5 million tax benefit a year earlier; after redomiciling to the U.S. on January 26, 2026, its statutory rate is the U.S. federal rate of 21%. Diluted shares fell to 122 million from 129 million after $302 million of share repurchases in the first nine months of 2026. (Indivior Form 10-Q, Q3 2026, Oct 29, 2026; Indivior Q3 2026 release, Oct 29, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Indivior said with Q3 2026 results that it was on track to meet its stand-alone full-year 2026 guidance: net revenue of $1,295 million to $1,365 million, total SUBLOCADE net revenue of $1,010 million to $1,050 million, non-GAAP operating expenses of $430 million to $450 million and adjusted EBITDA of $700 million to $740 million. It said that guidance would no longer apply once the merger closed. (Indivior Q3 2026 release, Oct 29, 2026)

Before closing, Indivior declared a special cash dividend of $1,000 million in aggregate, equal to $8.13 per share, to holders of record on October 30, 2026. Indivior stockholders were expected to own approximately 56.5% of the combined company and Supernus stockholders approximately 43.5%. (Indivior Form 10-Q, Q3 2026, Oct 29, 2026)

A consensus figure is the average of the models published by the analysts who cover Indivior, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Indivior's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning INDV is on is INDV a buy or a sell?, what analysts expect next is on the INDV forecast, and what the company does is on the Indivior (INDV) stock page.

Every number on this page can be traced to a document Indivior published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.